ICTRP Search Portal

Main

Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.

Register:	ClinicalTrials.gov
Last refreshed on:	8 January 2018
Main ID:	NCT02461979
Date of registration:	31/05/2015
Prospective Registration:	No
Primary sponsor:	Sherief Abd-Elsalam
Public title:	The Role of the Vitamin D Receptor Gene Polymorphisms in Hepatocarcinogenesis
Scientific title:	The Role of the Vitamin D Receptor Gene Polymorphisms in Hepatocarcinogenesis in Cirrhotic Patients Infected With Chronic Hepatitis C Virus
Date of first enrolment:	February 2015
Target sample size:	50
Recruitment status:	Recruiting
URL:	https://clinicaltrials.gov/show/NCT02461979
Study type:	Interventional
Study design:	Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Other. Masking: None (Open Label).
Phase:	N/A

Countries of recruitment
Egypt

Contacts

Name:	Sherief Abd-elsalam, lecturer
Address:
Telephone:	00201095159522
Email:	Sheriefabdelsalam@yahoo.com
Affiliation:

Name:	Sherief Abdelsalam, lecturer
Address:
Telephone:	00201095159522
Email:	Sheriefabdelsalam@yahoo.com
Affiliation:

Name:	Fathia Asal, Prof
Address:
Telephone:
Email:
Affiliation:	hepatology dept-Tanta

Name:	WALAA Elkhalawany, lecturer
Address:
Telephone:
Email:
Affiliation:	hepatology dept-Tanta

Name:	Sherief abd-elsalm, lecturer
Address:
Telephone:
Email:
Affiliation:	hepatology dept-Tanta

Name:	Amal El Bendary, Professor
Address:
Telephone:
Email:
Affiliation:	Clinicalpathology dept-Tanta

Name:	Basma Shetaa, physician
Address:
Telephone:
Email:
Affiliation:	Tanta University

Key inclusion & exclusion criteria

Inclusion Criteria:

- Hcv cirrhotic patient with and without Hcc

Exclusion Criteria:

- Malignancy other than HCC

- Co-infection with Hepatitis B virus (HBV) and Human immunodeficiency virus (HIV)

- Cirrhosis is due to causes other than chronic hepatitis C

Age minimum: N/A
Age maximum: N/A
Gender: All

Health Condition(s) or Problem(s) studied

Liver Cancer

Intervention(s)

Other: The VDR genotype

Primary Outcome(s)

number of HCC patients with abnormal (APAL) VDR polymorphism [Time Frame: 6 months]

Secondary Outcome(s)

Secondary ID(s)

liver cancer

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Secondary Sponsor(s)

Tanta University

Ethics review

Results

Results available:
Date Posted:
Date Completed:
URL:

Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.